Impact of NO donor therapy with JS-K and temozolomide chemotherapy on tumor volume, perfusion and vascular permeability and survival in intracranial U87 xenografts in vivo

A. Weyerbrock, N. Osterberg, M. Ordikhani-Seyedlar, A. Werres, C. Weidensteiner & W. Reichardt
Objective: Insufficient drug delivery and chemoresistance limit response of gliomas to systemic therapy. JS-K, a diazeniumdiolate prodrug, allows specific release of nitric oxide (NO) after cleavage by GSTs. JS-K inhibits proliferation and induces apoptosis/necrosis in vitro and in vivo. The objective[for full text, please go to the a.m. URL]